Intercept says liver disease drug effective in trial

[Reuters] – Intercept Pharmaceuticals Inc said on Sunday its experimental liver disease drug was effective in a third late-stage clinical trial and that the results set the stage for the company to file for marketing approval. The drug, obeticholic acid more

View todays social media effects on ICPT

View the latest stocks trending across Twitter. Click to view dashboard

See who Intercept is hiring next, click here to view